Advertisement

Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model

  • Ming Chen
  • Min Xu
  • Chengliang Zhu
  • Hongling Wang
  • Qiu Zhao
  • Feng ZhouEmail author
Original Article

Abstract

Hepatocellular carcinoma (HCC) is the third most lethal cancer in the world. Natural killer (NK) cell-mediated immunity is crucial for tumor surveillance and therapy. Characterization of the regulatory mechanisms of NK cell function is important for developing novel immunotherapies against HCC. In this study, we used a chemical-induced mouse HCC model to identify the upregulation of Sirtuin2 (SIRT2) in liver NK cells. In particular, SIRT2 was predominantly expressed in liver CD94+ NK cells. The HCC liver microenvironment induced SIRT2 expression in NK cells. In addition, overexpression of exogenous SIRT2 significantly upregulated the production of cytokines and cytotoxic mediators in activated NK cells. Consistently, SIRT2-overexpressing NK cells showed a stronger tumoricidal effect on hepatoma cells. Moreover, SIRT2 remarkably promoted the phosphorylation of Extracellular-signal-regulated kinase 1/2 (Erk1/2) and p38 Mitogen-activated protein kinases (MAPK) in activated NK cells. SIRT2 knockdown in liver CD94+ NK cells impaired their cytotoxic effect on hepatoma cells. Our study indicates that SIRT2 enhances the tumoricidal activity of liver NK cells in HCC.

Keywords

Sirtuin2 NK cells Erk1/2 p38 Hepatocellular carcinoma 

Abbreviations

ACK

Ammonium–chloride–potassium

APC

Allophycocyanin

Erk

Extracellular-signal-regulated kinase

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GFP

Green fluorescent protein

HCC

Hepatocellular carcinoma

JNK

Jun N-terminal kinase

MAPK

Mitogen-activated protein kinases

MOI

Multiplicity of infection

NAD

Nicotinamide adenine dinucleotide

NK cells

Natural killer cells

NKG2

Natural killer group 2

PBS

Phosphate-buffered saline

RIPA

Radioimmunoprecipitation assay

SIRT

Sirtuin

Notes

Author contributions

MC conducted the animal model, cell sorting, quantitative RT-PCR, adoptive transfer, and in vitro culture. MX prepared the lentiviruses and performed the lentiviral transduction. CZ conducted the immunoblotting analysis. HW did the intracellular staining and flow cytometry analysis. QZ conducted the statistical analysis. FZ designed the experiments, analyzed the data and composed the manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (Grant No. 81470823) and the Natural Science Foundation of Hubei Province (Grant No. 2013CFB304).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

The animal study was approved by the Wuhan University Animal Care and Use Committee (animal research approval number: 11400700245566). The animal experiments were performed following the Wuhan University Animal Use Guidelines.

Informed consent

Not applicable because no human subjects were included.

Animal source

All mice were obtained from SBS Genetech Co, Ltd.

Cell line authentication

Not applicable because primary NK cells were used. The mouse hepatoma cell line Hepa1-6RAE1 was a gift from another lab (from Dr. Kai Dai, Wuhan University) so no authentication information was gained. The HEK293T cell line was purchased from Procell Life Science & Technology Co, Ltd. (Wuhan, China) and was not authenticated, because this cell line was only used for lentivirus packaging in the current study.

Supplementary material

262_2019_2337_MOESM1_ESM.pdf (269 kb)
Supplementary material 1 (PDF 269 kb)

References

  1. 1.
    Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M (2018) The immunology of hepatocellular carcinoma. Nat Immunol 19:222–232.  https://doi.org/10.1038/s41590-018-0044-z CrossRefGoogle Scholar
  2. 2.
    Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125:S272–S283.  https://doi.org/10.1016/j.jaci.2009.09.045 CrossRefGoogle Scholar
  3. 3.
    Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, Lopez-Diaz de Cerio A, Cabo M, Lopez-Botet M, Melero I (2017) Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol 45:73–81.  https://doi.org/10.1016/j.coi.2017.01.003 CrossRefGoogle Scholar
  4. 4.
    Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578.  https://doi.org/10.3389/fimmu.2015.00578 CrossRefGoogle Scholar
  5. 5.
    Daher M, Rezvani K (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146–153.  https://doi.org/10.1016/j.coi.2018.03.013 CrossRefGoogle Scholar
  6. 6.
    Rezvani K, Rouce R, Liu E, Shpall E (2017) Engineering natural killer cells for cancer immunotherapy. Mol Ther 25:1769–1781.  https://doi.org/10.1016/j.ymthe.2017.06.012 CrossRefGoogle Scholar
  7. 7.
    Sidorova-Darmos E, Wither RG, Shulyakova N, Fisher C, Ratnam M, Aarts M, Lilge L, Monnier PP, Eubanks JH (2014) Differential expression of sirtuin family members in the developing, adult, and aged rat brain. Front Aging Neurosci 6:333.  https://doi.org/10.3389/fnagi.2014.00333 CrossRefGoogle Scholar
  8. 8.
    Zhang J, Lee SM, Shannon S et al (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119:3048–3058.  https://doi.org/10.1172/JCI3890238902 CrossRefGoogle Scholar
  9. 9.
    Zou T, Yang Y, Xia F, Huang A, Gao X, Fang D, Xiong S, Zhang J (2013) Resveratrol Inhibits CD4+ T cell activation by enhancing the expression and activity of Sirt1. PLoS One 8:e75139.  https://doi.org/10.1371/journal.pone.0075139 CrossRefGoogle Scholar
  10. 10.
    Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G, Hancock WW (2011) Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol 31:1022–1029.  https://doi.org/10.1128/MCB.01206-10 CrossRefGoogle Scholar
  11. 11.
    van Loosdregt J, Brunen D, Fleskens V, Pals CE, Lam EW, Coffer PJ (2011) Rapid temporal control of Foxp3 protein degradation by sirtuin-1. PLoS One 6:e19047.  https://doi.org/10.1371/journal.pone.0019047 CrossRefGoogle Scholar
  12. 12.
    Kwon HS, Lim HW, Wu J, Schnolzer M, Verdin E, Ott M (2012) Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. J Immunol 188:2712–2721.  https://doi.org/10.4049/jimmunol.1100903 CrossRefGoogle Scholar
  13. 13.
    Dai K, Huang Y, Chen Z, Sun X, Yang L, Jiang Y (2018) Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model. Eur J Immunol 48:683–695.  https://doi.org/10.1002/eji.201747281 CrossRefGoogle Scholar
  14. 14.
    Yu J, Wei M, Mao H et al (2009) CD94 defines phenotypically and functionally distinct mouse NK cell subsets. J Immunol 183:4968–4974.  https://doi.org/10.4049/jimmunol.0900907 CrossRefGoogle Scholar
  15. 15.
    Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, Hamann J, Kuijpers TW, van Lier RA (2008) CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol 180:3739–3745CrossRefGoogle Scholar
  16. 16.
    Xu H, Li Y, Chen L, Wang C, Wang Q, Zhang H, Lin Y, Li Q, Pang T (2016) SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway. Int J Oncol 48:613–623.  https://doi.org/10.3892/ijo.2015.3275 CrossRefGoogle Scholar
  17. 17.
    She DT, Wong LJ, Baik SH, Arumugam TV (2018) SIRT2 inhibition confers neuroprotection by downregulation of FOXO3a and MAPK signaling pathways in ischemic stroke. Mol Neurobiol.  https://doi.org/10.1007/s12035-018-1058-0 Google Scholar
  18. 18.
    Fu B, Tian Z, Wei H (2014) Subsets of human natural killer cells and their regulatory effects. Immunology 141:483–489.  https://doi.org/10.1111/imm.12224 CrossRefGoogle Scholar
  19. 19.
    Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X, Ren H, Zhang DZ (2017) Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol 14:819–829.  https://doi.org/10.1038/cmi.2016.28 CrossRefGoogle Scholar
  20. 20.
    Bosch-Presegue L, Vaquero A (2014) Sirtuins in stress response: guardians of the genome. Oncogene 33:3764–3775.  https://doi.org/10.1038/onc.2013.344 CrossRefGoogle Scholar
  21. 21.
    Buler M, Andersson U, Hakkola J (2016) Who watches the watchmen? Regulation of the expression and activity of sirtuins. FASEB J 30:3942–3960CrossRefGoogle Scholar
  22. 22.
    Anwar T, Khosla S, Ramakrishna G (2016) Increased expression of SIRT2 is a novel marker of cellular senescence and is dependent on wild type p53 status. Cell Cycle 15:1883–1897.  https://doi.org/10.1080/15384101.2016.1189041 CrossRefGoogle Scholar
  23. 23.
    Collin R, St-Pierre C, Guilbault L et al (2017) An unbiased linkage approach reveals that the p53 pathway is coupled to NK cell maturation. J Immunol 199:1490–1504.  https://doi.org/10.4049/jimmunol.1600789 CrossRefGoogle Scholar
  24. 24.
    Wu G, Song C, Lu H, Jia L, Yang G, Shi X, Sun S (2014) Sirt2 induces C2C12 myoblasts proliferation by activation of the ERK1/2 pathway. Acta Biochim Biophys Sin (Shanghai) 46:342–345.  https://doi.org/10.1093/abbs/gmt151 CrossRefGoogle Scholar
  25. 25.
    Jung YJ, Lee AS, Nguyen-Thanh T, Kim D, Kang KP, Lee S, Park SK, Kim W (2015) SIRT2 regulates LPS-induced renal tubular CXCL2 and CCL2 expression. J Am Soc Nephrol 26:1549–1560.  https://doi.org/10.1681/ASN.2014030226 CrossRefGoogle Scholar
  26. 26.
    Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL (2007) Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. Proc Natl Acad Sci USA 104:6329–6334.  https://doi.org/10.1073/pnas.0611655104 CrossRefGoogle Scholar
  27. 27.
    Trotta R, Fettucciari K, Azzoni L, Abebe B, Puorro KA, Eisenlohr LC, Perussia B (2000) Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol 165:1782–1789CrossRefGoogle Scholar
  28. 28.
    Yu M, Luo H, Fan M et al (2018) Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther 26:366–378.  https://doi.org/10.1016/j.ymthe.2017.12.012 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Ming Chen
    • 1
  • Min Xu
    • 2
  • Chengliang Zhu
    • 3
  • Hongling Wang
    • 4
  • Qiu Zhao
    • 4
  • Feng Zhou
    • 4
    Email author
  1. 1.Department of Blood TransfusionZhongnan Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of Hematology and Oncology, Wuhan Children’s Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Department of Clinical LaboratoryRenmin Hospital of Wuhan UniversityWuhanChina
  4. 4.Hubei Clinical Center and Key Laboratory for Intestinal and Colorectal Disease, Department of GastroenterologyZhongnan Hospital of Wuhan UniversityWuhan CityChina

Personalised recommendations